3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hypereosinophilic Syndrome
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
16
fludarabine
9
fludarabine phosphate
8
Rituximab
5
Whole-Body Irradiation
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Melphalan
4
Cytarabine
4
Busulfan
4
Azacitidine
4
AP 1903 reagent
4
venetoclax
3
ruxolitinib
3
ibrutinib
3
Tacrolimus
3
Prednisone
3
Methotrexate
3
Mesna
3
Etoposide
3
pegaspargase
2
obinutuzumab
2
ivosidenib
2
Vincristine
2
Patient Reported Outcome Measures
2
Observation
2
Mercaptopurine
2
Leucovorin
2
Doxorubicin
2
Dexamethasone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia
×
pevonedistat
×
Clear all
NCT04090736
2025-03-17
PEVOLAM
PETHEMA Foundation
Phase 3
Active not recruiting
302 enrolled